• LAST PRICE
    1.6600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.5400/ 5
  • Ask / Lots
    1.7900/ 4
  • Open / Previous Close
    0.0000 / 1.6600
  • Day Range
    ---
  • 52 Week Range
    Low 1.1900
    High 3.7800
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.63
TimeVolumeGALT
09:32 ET27301.63
09:34 ET2001.63
09:43 ET2001.6376
09:52 ET6001.6349
10:01 ET2181.65
10:03 ET82151.6398
10:15 ET1601.6376
11:33 ET2001.66
11:42 ET4001.64
11:44 ET1001.6414
11:47 ET246801.54
12:16 ET15001.57
12:21 ET8051.58
01:01 ET1001.59
01:15 ET25971.6
01:17 ET4001.61
02:06 ET5001.62
02:08 ET1001.61
02:09 ET2791.6
02:49 ET2001.64
02:56 ET1001.64
03:00 ET11001.6204
03:21 ET1001.66
03:27 ET1001.65
03:30 ET12501.6319
03:39 ET8001.62
03:52 ET7421.6
03:54 ET2041.66
03:56 ET2141.66
03:57 ET1001.65
03:59 ET3261.66
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGALT
Galectin Therapeutics Inc
91.5M
-2.8x
---
United StatesCADL
Candel Therapeutics Inc
97.9M
-3.9x
---
United StatesIMUX
Immunic Inc
91.7M
-1.1x
---
United StatesDBTX
Decibel Therapeutics Inc
98.6M
-1.4x
---
United StatesBIXT
Bioxytran Inc
91.4M
-16.3x
---
United StatesCKPT
Checkpoint Therapeutics Inc
90.9M
-1.2x
---
As of 2022-10-04

Company Information

Galectin Therapeutics Inc. is a biotechnology company that is focused on developing therapies to improve the lives of patients with fibrotic disease, chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, which is a belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis (NASH) patients. The Company also designed a Phase IIb/III clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis cirrhosis.

Contact Information

Headquarters
SUITE 240 4960 PEACHTREE INDUSTRIAL BOULEVARDNORCROSS, GA, United States 30071
Phone
678-620-3186
Fax
770-864-1327

Executives

Independent Chairman of the Board
Richard Uihlein
President, Chief Executive Officer, Director
Joel Lewis
Chief Financial Officer
Jack Callicutt
Executive Vice President - Manufacturing and Product Development
Eliezer Zomer
Vice President - Commercial Development, Regulatory Affairs and Quality Assurance
J. Rex Horton

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$91.5M
Revenue (TTM)
$0.00
Shares Outstanding
59.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.93
EPS
$-0.60
Book Value
$0.04
P/E Ratio
-2.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.